rs380390

This variant is located in the CFH gene.

GWAS Catalog Trait Associations (1)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

age-related macular degeneration

Klein RJ et al. Complement factor H polymorphism in age-related macular degeneration. Science (new York, N.y.) 308(5720):385-9 (2005)
Allele C
OR 4.60
p 4.0e-8
N 146
Small GWAS
European

Research that mentions this SNP (1)

Evidence for association between multiple complement pathway genes and AMD
AssociationN=146Valentin Dinu et al.(2007)· Genetic Epidemiology

A pathway-focused genetic analysis identified associations between complement pathway genes and age-related macular degeneration (AMD) subtypes using 146 AMD cases and controls. The study confirmed the previously identified CFH Y402H variant (rs1061170) strongly associated with AMD (OR 0.16-0.35 for protection), and identified two additional complement pathway genes—C7 and MBL2—potentially associated with disease progression, particularly the C7 H2 haplotype (rs2329434/rs2876849 variants) that conferred protection against wet AMD among CFH 402H homozygotes (p=0.001, OR 0.16, 95% CI 0.05-0.49).

Traits studied:Age-related macular degeneration (AMD)Dry AMDWet AMD

About CFH

This gene is a member of the Regulator of Complement Activation (RCA) gene cluster and encodes a protein with twenty short consensus repeat (SCR) domains. This protein is secreted into the bloodstream and has an essential role in the regulation of complement activation, restricting this innate defense mechanism to microbial infections. Mutations in this gene have been associated with hemolytic-uremic syndrome (HUS) and chronic hypocomplementemic nephropathy. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Oct 2011]

View all CFH variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…